$INSM

Lewis William sold $1.3M of INSM

Lewis William (Chair and CEO) sold 10,699 shares of INSMED Inc (INSM) at an average of $117.40 ($116.55–$118.52, $1.26M total) across 3 trades on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lewis William
Published Jul 10, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INSM
Neutral
high confidence
Mentioned
$INSM
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity (size, price range, and post-transaction holdings) but does not introduce new fundamentals.

02

Market read

This is primarily a sentiment and positioning datapoint for INSM, not a fundamental catalyst.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, trials, or financing, the signal is usually weak.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-10 after trades dated 2026-07-09.

Background

The article is an SEC Form 4 insider transaction disclosure for INSMED Inc, reporting open-market sales by the CEO and Chair.

Company-level read

Ticker impact

$INSMNeutralHigh confidence
Context

INSMED CEO and Chair Lewis William sold 10,699 shares in open-market trades under a pre-arranged 10b5-1 plan for about $1.26M.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless paired with other disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and it does not include new operating, regulatory, or financial guidance.

Market effects

No sector-level implications disclosed; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

A large CEO sale can be interpreted as liquidity management rather than bearish conviction because it is explicitly under a pre-arranged 10b5-1 plan.

Key entities

  • INSMED Inc

    Company whose Form 4 insider sale is disclosed.

  • Lewis William

    Chair and CEO who sold 10,699 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INSMHighAI 8/10

Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business

Insmed (INSM) reported Q2 2026 revenue of $425.5M, up 296% YoY, with net loss narrowing to $13.2M. BRINSUPRI sales reached $309.2M, up 49% QoQ. The company raised full-year BRINSUPRI guidance to $1.25B-$1.40B. Insmed also increased its peak revenue estimate for lead programs to over $14B. Expenses rose due to commercial buildout and R&D spending.

$INSMMedAI 8/10

Is Insmed (INSM) Undervalued Following Japan Approval For BRINSUPRI?

Insmed (INSM) received approval for BRINSUPRI in Japan, adding to U.S. and European clearances. Shares rose 2.78% to $121.84, with a 30-day return of 23.57% but a YTD decline of 31.21%. Analysts suggest a fair value of $197.14, indicating potential undervaluation, but risks include approval delays and reimbursement challenges.

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

$INSMHighAI 9/10

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Insmed Inc. (INSM) announced Japan's approval of BRINSUPRI® (brensocatib) for treating non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12+. The approval is based on Phase 3 ASPEN study results showing reduced pulmonary exacerbations and lower lung function decline. BRINSUPRI is now approved in the U.S., Europe, and Japan.

$INSMMed

How Insmed’s Sharply Narrowed Q2 2026 Net Loss At Insmed (INSM) Has Changed Its Investment Story

Insmed Inc. (INSM) reported a sharply narrowed net loss of $13.24M in Q2 2026, down from $321.69M a year earlier, with loss per share at $0.06 vs. $1.70. The company's H1 2026 net loss also improved to $176.81M from $578.27M, indicating lower cash burn. Insmed's investment narrative focuses on its respiratory portfolio, particularly brensocatib, with guidance projecting $1B in 2026 BRINSUPRI revenue and $450M-$470M from ARIKAYCE. The company aims for $4.1B revenue and $1B earnings by 2029, requi